Summary of data and estimated rates for fatal recurrent venous thromboembolism and fatal bleeding
| Fatal recurrent VTE | Fatal bleeding | ||||
| n/N | Event rate | HR (95% CrI) | n/N | Event rate | |
| Placebo or observation | 16/3621 | 0.27 (0.04–1.47) | Reference | 5/3611 | 0.07 (0.00–0.61) |
| Aspirin | 4/1747 | 0.16 (0.02–1.41) | 0.63 (0.13 to 2.68) | 1/1747 | 0.01 (0.00–0.20) |
| Low-intensity VKA | 1/624 | 0.03 (0.00–0.46) | 0.12 (0.00 to 1.11) | 0/624 | 0.00 (0.00–0.00) |
| Standard-intensity VKA | 13/6067 | 0.10 (0.01–0.64) | 0.39 (0.11 to 1.13) | 5/6070 | 0.04 (0.00–0.52) |
| Low-dose factor Xa inhibitor | 2/1967 | 0.05 (0.00–0.47) | 0.20 (0.02 to 00.99) | 0/1967 | 0.00 (0.00–0.00) |
| Standard-dose factor Xa inhibitor | 16/6155 | 0.16 (0.02–0.96) | 0.60 (0.20 to 1.71) | 1/6151 | 0.01 (0.00–0.13) |
| Direct thrombin inhibitor | 1/2111 | 0.02 (0.00–0.35) | 0.09 (0.00 to 0.83) | 0/2114 | 0.00 (0.00–0.00) |
*Heterogeneity was 0.41 (0.02 to 1.39) for fatal recurrent VTE.
†Heterogeneity was 0.96 (0.04 to 1.94) for fatal bleeding.
‡Event rates are presented in per 100 patient-years.
§The aggregated hazards estimated by modelling data on the respective arms of studies into the Poisson likelihood are presented in the median (95% CrI).
CrI, credible interval; VKA, vitamin K antagonist; VTE, venous thromboembolism.